Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis 46202, USA.
Journal of Clinical Oncology (Impact Factor: 18.04). 05/2011; 29(15):2060-5. DOI: 10.1200/JCO.2010.32.9607
Source: PubMed

ABSTRACT The purpose of this study was to evaluate the impact of carboplatin and paclitaxel in patients with advanced previously untreated thymoma and thymic carcinoma.
We conducted a prospective multicenter study in patients with unresectable thymoma (n = 21) or thymic carcinoma (n = 23). Patients were treated with carboplatin (area under the curve, 6) plus paclitaxel (225 mg/m(2)) every 3 weeks for a maximum of six cycles. The primary end point of this trial was to evaluate the objective response rate.
From February 2001 through January 2008, 46 patients were enrolled. Thirteen patients had grade 4 or greater toxicity, mostly neutropenia. Using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria, three complete responses (CRs) and six partial responses (PRs; objective response rate [ORR], 42.9%; 90% CI, 24.5% to 62.8%) were observed in the thymoma cohort; 10 patients had stable disease. For patients with thymic carcinoma, no CRs and five PRs (ORR, 21.7%; 90% CI, 9.0% to 40.4%) were observed; 12 patients had stable disease. Progression-free survival (PFS) was 16.7 (95% CI, 7.2 to 19.8) and 5.0 (95% CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively. To date, only seven patients (33.3%) with thymoma have died, compared with 16 patients (69.6%) with thymic carcinoma. Median survival time was 20.0 months (95% CI, 5.0 to 43.6 months) for patients with thymic carcinoma, but it has not been reached for patients with thymoma.
Carboplatin plus paclitaxel has moderate clinical activity for patients with thymic malignancies, but this seems less than expected with anthracycline-based therapy. Patients with thymic carcinoma have poorer PFS and overall survival than patients with thymoma.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Twenty-eight patients treated with neoadjuvant chemotherapy for invasive thymoma are presented. METHODS: The patients were 16 men and 12 women between the ages of 23 and 75 years (mean = 50.8 years). All patients were treated with a similar modality consisting of three courses of cyclophosphamide, doxorubicin, cisplatin, and prednisone prior to their surgical resection. RESULTS: Grossly, all tumors were ill-defined invasive masses ranging in size from 5 to 18 cm in greatest dimension. Histological evaluation of the resected tumors showed a gamut of histological features, including necrosis, cystic changes, hemorrhage, histiocytic proliferation, calcifications, and cholesterol cleft granulomas in varying proportions. In addition, we found that some histological types of thymoma appeared to be affected less by neoadjuvant chemotherapy, while others, mainly those tumors with a more prominent lymphocytic component, showed more extensive histological changes. CONCLUSIONS: Based on the results of this study, it appears that the response to induction chemotherapy in thymomas may be determined by the histological characteristics of the tumor, with treatment-related changes being present predominantly in cases in which the tumor had a prominent lymphocytic component (WHO type B1 and B2), while tumor viability was highest in cases where the histological type corresponded to spindle cell and atypical thymomas (WHO types A and B3, respectively). In addition, it has to be noted that the histological changes attributed to treatment effect may also be seen in untreated tumors thereby not allowing for definitive separation of treated from nontreated thymomas.
    Beiträge zur Klinik der Tuberkulose 05/2013; · 2.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thymic carcinoma is a rare cancer that is more aggressive and shows a poorer prognosis compared with thymoma. Molecular analysis has demonstrated that this entity is clearly distinct from thymoma. However, no definitive clinical management has been reported, and the roles of chemotherapy and radiotherapy for advanced thymic carcinoma remain unclear given the rarity of this clinicopathology. The current study reports the case of a 65yearold male who presented with advanced thymic carcinoma with solitary brain and pulmonary metastases, but demonstrated longterm survival following multiple lines of chemotherapy and radiotherapy with palliative intent. Although the solitary brain metastasis was well controlled for several years using wholebrain irradiation, cognitive function gradually declined with cerebral atrophy. Thymic carcinoma is known to show a poor prognosis and aggressive clinical progress, however, it occasionally demonstrates a clinically indolent course. Modalities of treatment should thus be selected prudently to avoid toxicity, in consideration of the possibility of longterm survival. Stereotactic radiation therapy for brain metastases, including cyberknife or γknife surgery, appears to represent the optimal local treatment for such patients with unexpectedly longer survival due to indolent thymic carcinoma.
    Oncology letters 01/2014; 8(2). · 0.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Malignancies originating from thymic epithelial tissue are rare and treatment approach depends on the individual situation. There are no randomized trials that provide evidence of therapy for patients with thymoma and thymic carcinoma. Treatment includes surgery, radiation therapy, and systemic therapy. For early stage tumors, surgery is the treatment of choice. Long-term survival depends on histologic type, presence of invasion, and quality of surgical resection. For locally advanced thymomas and thymic carcinomas, multimodal treatment includes neoadjuvant chemotherapy and adjuvant radiation. Patients with metastatic tumors are mainly treated with palliative chemotherapy. The optimal chemotherapy combination has not yet been established, although platinum-based drug regimes show reasonable response rates. For patients with poor performance status, the somatostatin (SST) analog octreotide with high affinity for SST receptors could be a potential treatment alternative. Small trials showed tumor responses, especially in combination with prednisolone. In the last decade, an effort has been made to establish targeted agents in the treatment of thymomas and thymic carcinomas. Nevertheless, up to now these agents have had only limited activity in this rare malignancy.
    memo - Magazine of European Medical Oncology 01/2013; 6(1).


1 Download
Available from